• Azithromycin

1/1

Azithromycin NEW

$56.00 50mg
$84.00 100mg
$219.00 500mg
  • Min. Order
  • Purity99.97%
  • Cas No83905-01-5
  • Supply Ability10g
  • Update time2026-03-13

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.
VIP6Y
United StatesUnited States
Enterprise Verified
Business Bank account Basic Contact Infomation Business Address Trade Company
Chemical Properties
Product Name Azithromycin
CAS No 83905-01-5
EC-No
Min. Order
Purity 99.97%
Supply Ability 10g
Release date 2026/03/13

Company Profile Introduction

Citations

[1] Kaw, H. Y., Yu, J., Ma, X., Yang, Q., Zhu, L., & Wang, W. (2024). The significance of environmentally bioavailable antimicrobials in driving antimicrobial resistance in soils. Environment International, 190, Article 108830. https://doi.org/10.1016/j.envint.2024.108830
[2] Li, Hongying, Li, Jianrui, Li, Jiayu, Li, Hu, Wang, X., Jiang, J., Lei, L., Sun, H., Tang, M., Dong, B., He, W., Si, S., Hong, B., Li, Y., Song, D., Peng, Z., Che, Y., & Jiang, J.-D. (2024). Carrimycin inhibits coronavirus replication by decreasing the efficiency of programmed –1 ribosomal frameshifting through directly binding to the RNA pseudoknot of viral frameshift-stimulatory element. Acta Pharmaceutica Sinica. B, 14 6, Pages 2567-2580. https://doi.org/10.1016/j.apsb.2024.02.023
[3] Nicholson, M. W., Huang, C.-Y., Wang, J.-Y., Ting, C.-Y., Cheng, Y.-C., Chan, D. Z. H., Lee, Y.-C., Hsu, C.-C., Hsu, Y.-H., Chang, C. M. C., Hsieh, M. L., Cheng, Y.-Y., Lin, Y.-L., Chen, C.-H., Wu, Y.-T., Hacker, T. A., Wu, J. C., Kamp, T. J., & Hsieh, P. C. H. (2022). Cardio- and Neurotoxicity of Selected Anti-COVID-19 Drugs. Pharmaceuticals (Basel, Switzerland). https://doi.org/10.3390/ph15060765
[4] Xu, K.-K., Huang, Y.-K., Liu, X., Zhang, M.-C., & Xie, H.-T. (2020). Organotypic Culture of Mouse Meibomian Gland: A Novel Model to Study Meibomian Gland Dysfunction In Vitro. Investigative Ophthalmology & Visual Science, 30. https://doi.org/10.1167/iovs.61.4.30
[5] Fan, Y., Li, M., Ma, K., Hu, Y., Jing, J., Shi, Y., Li, E., & Dong, D. (2019). Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway. Cancer Biology & Therapy, 20 5, 617–632. https://doi.org/10.1080/15384047.2018.1539290

You may like

Recommended supplier